Living Medical Textbook - Oncology - Projects In Knowledge - Women's Cancers Edition Table of Contents - Targeted Agents and Chemotherapy Options for HER2-Positive and HER2-Negative Metastatic Breast Cancer CME Information

Chapter 6 – Targeted Agents and Chemotherapy Options for HER2-Positive and HER2-Negative Metastatic Breast Cancer

Contributing Editor
	Monica Fornier, MD Breast Cancer Medicine Service Memorial Sloan-Kettering Cancer Center New York, New York	Patrick G. Morris, MD, MSc, MRCPI Special Fellow in Breast Medicine Breast Cancer Medicine Service Memorial Sloan-Kettering Cancer Center New York, New York

top

Activity Goal
The goal of this CME activity is to examine current and emerging strategies for treating and managing patients with breast cancer.

Target Audience
This CME activity is designed for medical oncology clinicians, gynecologists, primary care physicians and other clinicians who interact with and/or treat women with breast cancer.

Learning Objectives

•	Choose first-line treatment for women with metastatic breast cancer based on HER2 and hormone-receptor status in order to improve patient survival outcomes.
•	Compare the mechanism of action and efficacy of treatment options for women with HER2-negative tumors resistant to anthracyclines or taxanes.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Monica Fornier, MD, is on the speakers bureau of Bristol-Myers Squibb.

Patrick G. Morris, MD, MSc, MRCPI, has received honoraria from Eisai Inc, Genomic Health, Haymarket Media Inc, and Pfizer Inc.

Nancy J. Nordenson, MT (ASCP), MFA (medical writer), has disclosed no significant relationships.

Off-Label Drug Statement: The following drugs are not approved for the treatment of metastatic breast cancer: alvespimycin, dasatinib, ertumaxomab, geldanamycin, pertuzumab, tanespimycin, and trastuzumab-DM1.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top

1863.06